Oncologic Outcomes After Neoadjuvant Chemoradiation Followed by Curative Resection With Tumor-Specific Mesorectal Excision for Fixed Locally Advanced Rectal Cancer
- 1 December 2006
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Surgery
- Vol. 244 (6), 1024-1030
- https://doi.org/10.1097/01.sla.0000225360.99257.73
Abstract
Objective: The purpose of this study was to determine the oncologic outcomes and clinical factors affecting survival in patients who underwent neoadjuvant chemoradiotherapy following tumor specific mesorectal excision for locally advanced, fixed rectal cancer. Summary Background Data: Neoadjuvant chemoradiation therapy has resulted in significant tumor downstaging, which enhances curative resection and subsequently improves local disease control for rectal cancer. However, oncologic outcomes, according to clinical factors, have not yet been fully understood in locally advanced and fixed rectal cancer. Methods: A total of 114 patients who had undergone neoadjuvant chemoradiation for advanced rectal cancer (T3 or T4 and node positive) were investigated retrospectively. Chemotherapy was administered intravenously with 5-FU and leucovorin during weeks 1 and 5 of radiotherapy. The total radiation dose was 5040 cGY in 25 fractions delivered over 5 weeks. Tumor-specific mesorectal excision was done 4 to 6 weeks after the completion of neoadjuvant chemoradiation. Survival and recurrence rates, according to the pathologic stage, were evaluated. Moreover, factors affecting survival were investigated. Results: The 5-year survival rates according to pathologic stage were: 100% in pathologic complete remission (n = 10), 80% in stage I (n = 23), 56.8% in stage II (n = 34), and 42.3% in stage III (n = 47) (P = 0.0000). Local, systemic, and combined recurrence rates were 11.4%, 22.8%, and 3.5%, respectively. Multivariate analysis showed that the pathologic N stage and operation method were the independent factors affecting survival rate. Conclusion: Pathologic complete remission showed excellent oncologic outcomes, and the pathologic N stage was the most important factor for oncologic outcomes.Keywords
This publication has 36 references indexed in Scilit:
- Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survivalJournal of Gastrointestinal Surgery, 2005
- A Pathologic Complete Response to Preoperative Chemoradiation Is Associated With Lower Local Recurrence and Improved Survival in Rectal Cancer Patients Treated by Mesorectal ExcisionDiseases of the Colon & Rectum, 2003
- Efficacy of Preoperative Radiation Therapy for Resectable Rectal Adenocarcinoma When Combined With Oral Tegafur-Uracil Modulated With LeucovorinDiseases of the Colon & Rectum, 2002
- Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patientsJournal of the American College of Surgeons, 2002
- Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinomaDiseases of the Colon & Rectum, 2001
- p53, BCL-2, and Ki-67 Expression According to Tumor Response After Concurrent Chemoradiotherapy for Advanced Rectal CancerAnnals of Surgical Oncology, 2001
- Neoadjuvant Chemoradiation for Rectal Cancer: Analysis of Clinical Outcomes From a 13-Year Institutional ExperienceAnnals of Surgery, 2001
- Rectal CancerArchives of Surgery, 1998
- Preoperative assessment of mesorectal lymph node involvement in rectal cancerBritish Journal of Surgery, 1989
- Pre-Operative assessment of local invasion in rectal cancer: Digital examination, endoluminal sonography or computed tomography?British Journal of Surgery, 1986